Remove 2007 Remove Doctors Remove FDA Approval
article thumbnail

FDA-Approved Labeling: Is Enough Enough?

FDA Law Blog: Biosimilars

Livornese — I saw the sign…and the answer is no—FDA-approved labeling apparently is not enough under state failure-to-warn laws, according to certain courts. That requirement would only be fulfilled if FDA agreed to such a change. But we digress. And indeed, after Pliva v.

article thumbnail

Researchers uncover genetic factors for severe Lassa fever

Broad Institute

Related news Scientific coalition developing surveillance system for detecting emerging pandemics in real-time While combing through the human genome in 2007, computational geneticist Pardis Sabeti made a discovery that would transform her research career. Finding participants for the study would be challenging too.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Too Many Kids Still Get Antipsychotics They Don’t Need

The Pharma Data

However, doctors are continuing to prescribe the drugs “off-label” for kids with conditions like attention deficit hyperactivity disorder (ADHD), anxiety, depression and conduct disorders, the research found. SUNDAY, Nov. The medications don’t have the safety and effectiveness data needed, nor do they have U.S. .

article thumbnail

Skinny Label and Induced Infringement: The Saga Continues

FDA Law Blog: Biosimilars

If an FDA-approved carve-out could support an intent to induce infringement claim, the use of the “section viii pathway would be substantially deterred.” Plainly, the Government brief states “The decision below is incorrect. The Government’s brief puts a lot of faith in the existing regulatory system rather than the patent system.

article thumbnail

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Agency IQ

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. The FDA maintains a webpage with the full rulemaking history for OTC nasal decongestant drug products.

Science 40
article thumbnail

Mifepristone Manufacturer Wins First Round in West Virginia

Drug & Device Law

The core premise of Bexis’ article is very simple: Once the FDA has said “yes” and approved a particular drug for a particular indication (“intended use”) for sale in the United States, federal preemption precludes any state from saying say “no” and trying to ban that same FDA-approved drug. In GenBioPro, Inc.

article thumbnail

Split Decision

Drug & Device Law

We discussed these concerns – which have since crystallized into what is called either the “municipal cost recovery rule” or the “free public services doctrine” – more detail back in one of the Blog’s early(2007) posts. In other words, the generic manufacturers are not allowed to change the FDA-approved label.